ENXTBR:ARGXBiotechs
Argenx (ENXTBR:ARGX) Stock Valuation After Expanded FDA Approval For Vyvgart And Pipeline Progress
argenx (ENXTBR:ARGX) has been in focus after the FDA expanded approval for its flagship drug Vyvgart to cover all adult patients with generalized myasthenia gravis, regardless of antibody status, drawing fresh attention to the stock.
See our latest analysis for argenx.
argenx’s recent FDA label expansion for Vyvgart and new rheumatology data have arrived alongside a 14.03% 1 month share price return and a 55.91% 1 year total shareholder return, indicating that momentum has been present over...